Sionna Therapeutics 1Q 2026: Revenue ($27.4M), Net income ($26.78M), EPS ($0.6) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
Sionna Therapeutics reported its 1Q 2026 results, showing revenue of $27.4M and a net income of $26.78M, with a diluted EPS of $0.6. Compared to the prior year, revenue increased by 65.6%, while net income rose by 62.5%. The company completed Phase 1 trials for SION-719 and SION-451 and is advancing to Phase 2a studies. Sionna maintains $289.9M in liquidity and has an ATM equity program to support operations through 2028.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments